Document is current
Any future updates will be listed below
-
Authors
Boggess, Steven C.
Gandhi, Vaidehi
Tsai, Ming-Chi https://orcid.org/0000-0002-6216-8672
Marzette, Emily https://orcid.org/0000-0002-1010-5848
Teyssier, Noam
Chou, Joanna Yu-Ying https://orcid.org/0009-0004-1227-2422
Hu, Xiaoyu
Cramer, Amber
Yadanar, Lin
Shroff, Kunal https://orcid.org/0000-0002-3803-7517
Jeong, Claire G.
Eidenschenk, Celine
Hanson, Jesse E. https://orcid.org/0000-0003-3059-5132
Tian, Ruilin https://orcid.org/0000-0001-7680-6682
Kampmann, Martin https://orcid.org/0000-0002-3819-7019
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (U54 NS123746)
California Institute for Regenerative Medicine (EDUC2-12730)
Alzheimer's Association (23AARF-1027616)
- License Information
-
More Information
Article History
Received: 5 June 2025
Accepted: 14 July 2026
First Online: 1 August 2026
Ethics
Competing interests: M.K. is a co-scientific founder of Montara Therapeutics and serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Alector, and Montara Therapeutics, and is an advisor to Modulo Bio and Theseus Therapies. M.K. is an inventor on US Patent 11,254,933 related to CRISPRi and CRISPRa screening, and on a US Patent application on in vivo screening methods. M.T., X.H., A.C., C.G.J., C.E., and J.H. are employees of Genentech. S.C.B. is currently employed at the Arc Institute (Palo Alto, CA). The remaining authors declare no competing interests.
